An Update on the Use of OrthoBiologics: Use of Biologics for Osteoarthritis

Abstract Osteoarthritis is a highly prevalent joint disorder affecting over 30 million adults in the United States. This debilitating disorder is associated with pain and decreased physical function. Though total joint arthroplasty is generally successful, this procedure has associated risk and many patients still have residual pain. Non-operative treatments have been investigated to provide patients with durable pain relief while not exposing them to increased risk. Orthobiologics, such as platelet-rich plasma, bone marrow aspirate concentrate, and amniotic products, contain cytokines and/or mesenchymal progenitor cells that have been demonstrated to modulate the pathogenesis of osteoarthritis in animal and basic science models and may provide clinical improvement in the clinical setting. This chapter will cover recent clinical trials involving orthobiologic injections in patients with hip or knee osteoarthritis.